Blog

/Blog/

The House Passes The 21st Century Cures Act – On To The Senate

Last Wednesday the House passed with a vote of 392 to 26, a medical innovation bill known as the 21st Century Cures Act, aimed at curing diseases, with the measure securing bipartisan support after months of negotiations. The bill’s goals are to speed up the Food and Drug Administration’s approval of new drugs while also investing [...]

Cognition and Hormone Therapy (ADT)

There have been numerous studies examining the how hormone deprivation (ADT), in the treatment of prostate cancer, has on a man’s cognition. There have been contradictor studies about this issue, however having had the experience and the honor of dealing with so many men with prostate cancer treated with androgen deprivation therapy (ADT), as well [...]

Thanksgiving in USA – Thank You

I've been leading Malecare Cancer Support for nineteen years.  You have honored me by sharing your time, voice and heart in one or more of our programs.  Thank you for that! You have taught me a lot about happiness, disease, hurt and fear.  You've shown me respect, made me laugh, and challenged me when I was [...]

By | November 22nd, 2016|Uncategorized|0 Comments

Politics As Usual As Congress Prepares To Not Pass The Budget – A Potential Devastating Problem for Medical Research

It is deeply troubling  to learn that Congress is considering not completing the fiscal year 2017 budget appropriations process.  Because of the normal political fighting that we still see in Washington, Congress is now considering passing a short-term or even long-term budget continuing resolution instead of the negotiated budget resolution they have worked so hard [...]

By | November 18th, 2016|Advanced Prostate Cancer, Advocacy, DOD, DOD PCRP, NIH, Research, Uncategorized|0 Comments

Vitamin D3 Potentiates Metformin in DU145 Human Prostate Cancer Cells

It is well established that common drugs like Metformin and vitamin D? exhibit a strong anti-proliferative action in many cancer cell lines. Recent research confirms that this is also true in human prostate cancer cells. In a recent study it was demonstrated that the combination of the two drugs, metformin and vitamin D3, had a [...]

By | November 17th, 2016|Advanced Prostate Cancer, Metformin, Research, Uncategorized, Vitamine D3|0 Comments

“Do No Harm” NOT in Hippocratic Oath

I was talking to a prostate cancer patient about the difference between "harm" and "hurt," referring to the Hippocratic Oath.  Doctors are ok with "hurting" patients regarding impotence and incontinence, but do all they can to prevent "harm," or death.  Both of us agreed this distinction relates to the Hippocratic Oath.  But, turns out we [...]

By | November 15th, 2016|Uncategorized|0 Comments

Over 20,000 Have Pledged to Boycott CVS & Caremark until they sell Cancer Drugs Again- CVS removing many cancer drugs, including Xtandi, from it’s formulary

Sign pledge to boycott CVS here: http://bit.ly/2gAJlno CVS Pharmacy will hurt many cancer patients by removing dozens of cancer treatment drugs, like leukemia drug Tasigna, prostate cancer drug Xtandi and chemotherapy treatment drug Neupogen, from their formulary, starting in 2017. CVS claims these drugs cost too much. Go ahead and tell that to my insurance [...]

By | November 3rd, 2016|Advanced Prostate Cancer, Advocacy, Uncategorized|0 Comments

Oncotype DX® Now Validated for Adverse Pathology, Biochemical Recurrence, Metastasis and Prostate Cancer Specific Death

In a press release issued yesterday, Genomic Health Inc. announced topline results from their clinical validation study of its biopsy-based Oncotype DX® Genomic Prostate Score™ (GPS). The study met its primary endpoint by demonstrating that Oncotype DX® test is a strong predictor for the development of metastasis and also prostate cancer death in men with early-stage prostate [...]

The 5 Important Questions We Need To Ask Men Who Are End Stage – Handling Grief

Advanced prostate cancer will eventually end, barring another cause of death, with the demise of the individual survivor. Knowing that you suffer from a terminal illness is hard, it is hard on the family and it is hard on the individual. Many of us don’t think about it, but it is also hard for many [...]

Enzalutamide Prescribing Info Includes New Information

Enzalutamide (Xtandi) has a new, expanded FDA label. The new label conforms with the clinical trial (TERRAIN) results that Xtandi is a superior drug to Casodex (bicalutamide) for men with metastatic castration-resistant prostate cancer (CRPC). The updated product label shows enzalutamide reduces the risk of radiographic progression or death by 40% vs. bicalutamide. Median radiographic [...]

By | October 26th, 2016|Advanced Prostate Cancer, Casodex, enzalutamide, Uncategorized, Xtandi|0 Comments